Korro Bio announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Knobil most recently served as Chief Medical Officer at Agilent Technologies, where she established an industry-leading medical affairs organization and was responsible for integrating the voice of patients into business and clinical development strategy and decision-making.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro to Participate in Upcoming September Investor and Scientific Conferences
- Starbucks, Chipotle upgraded: Wall Street’s top analyst calls
- Korro Bio initiated with an Outperform at William Blair
- Korro Bio reports Q2 EPS ($2.43), consensus ($2.39)
- Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates